|
|
|
|
Monday, April 13, 2020
Neovasc Inc. (NVCN)
Two Breakthrough Medical Technologies for Cardiovascular Markets
Neovasc Inc is a specialty medical device company. The company develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Tiara for the transcatheter treatment of mitral valve disease and the Neovasc Reducer for the treatment of refractory angina. Neovasc is developing the Tiara for the treatment of mitral valve disease. Neovasc operates its business in one segment.
Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.
Ahu Demir, Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
We are initiating coverage on Neovasc, Inc.
The Reducer for the Treatment of Refractory Angina. Neovasc is seeking FDA approval to commercialize the Reducer for the treatment of refractory angina in the United States. Patients suffering from refractory angina, a debilitating disease characterized by chronic chest pain, do not have any effective therapeutic options. The Reducer, commercially available in Europe, but not in United States, is a medical device designed to alleviate symptoms and improve heart functions.
Tiara for the Treatment of Mitral Valve Regurgitation. Neovasc is developing a medical device system known as Tiara for the treatment of patients suffering from mitral valve regurgitation, a disease caused by a malfunctioning of the heart’s native mitral valve. Neovasc’s system is designed to replace the defective native mitral valve for the Tiara prosthetic valve. Neovasc is currently seeking CE Mark to commercialize Tiara in Europe first, and…
Get the full report on Channelchek desktop.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst
certification and important disclosures included in the full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.